A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma
Active, not recruitingCTIS2023-509604-15-00
AstraZeneca ABAdvanced Renal Cell Carcinoma
Start: 2021-02-15Target: 93Updated: 2025-11-20